Abstract 2149P
Background
Catheter-related thrombosis (CRT) is the most frequent non-infectious complication regarding central venous devices (CVC). Its incidence has been reported 13% and 66% in symptomatic and asymptomatic patients, respectively, with several factors influencing its development.
Methods
CRT events recorded at TESEO between 2018 and 2023 were assessed. Descriptive and association analysis for rethrombosis and bleeding regarding location of thromboembolic event (TE) was conducted.
Results
A total of 245 patients developed CRT. Mean age was 60.5 years (SD 12.3). Ninety-one percent were ECOG ≤1. Most prevalent comorbidities were HTA (28.6%) and dyslipidemia (28.2%), with other TE-associated risk factors being ≤10%. PICC was present in 42.1%, PAC in 40.9% while 17% were missing. Previous VTE was present in 9.8% of patients, while 4.5% and 4.4% were on antiplatelet and anticoagulation therapy, respectively. Colorectal and breast cancers were the primary locations in 26.9% and 21.2%. Metastatic disease was observed in 54.3%. Cytotoxic chemotherapy was used in 80.4%, radiotherapy in 22.9% and 53.9% had the primary tumor resected. PE was present in 6.5%, being clinically suspected in 56.2% of cases. The diagnosis was mainly unilateral (81.3%) and 50% were central. VTE – related symptoms occurred in 70.2% of cases at presentation. LMWH was used in 91% and hospital admission was advised in 20.8% of cases. VTE – related complications were observed in 2%, being PE and superior vena cava syndrome the most frequent (40%). Arterial and venous rethrombosis were present in 0.8% and 4.9%. Minor bleeding episodes occurred in 2.5% of cases, while major/clinically relevant episodes were present in 3.6%. There was no association between rethrombosis and TE location (pulmonary embolism (PE) vs deep vein thrombosis (DVT), OR 2.57 (95% CI 0.52 – 12.6; p = 0.245)). An increased risk for major and minor bleeding was observed for PE compared to DVT (OR 6.58 (95% CI 1.8 – 23.7)).
Conclusions
Usual TE – associated risk factors were infrequent. CRT was symptomatic in most cases, with reduced complication rates after treatment. A probable association of bleeding risk and no differences for rethrombosis were observed for PE events.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Sociedad Española de Oncología Médica.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2237P - Avelumab (AVE), cetuximab (CET) and irinotecan (IRI) for treatment refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC): Translational analyses of the AVETUXIRI phase II trial
Presenter: Nicolas Huyghe
Session: Poster session 07
2238P - Tebentafusp reprograms immunosuppressive tumor-associated M2 macrophages towards anti-tumoral M1 macrophages
Presenter: Josep M. Piulats
Session: Poster session 07
2239P - Gene expression profiling in tumors with and without tertiary lymphoid structures across cancer-types
Presenter: Elia Segui Solis
Session: Poster session 07
2240P - Novel genetic markers associated with immune checkpoint inhibitor induced immune-related adverse events
Presenter: Ik Shin Chin
Session: Poster session 07
2241P - A novel 89Zr-anti-PD-1 immuno-PET-CT may predict response to PD-1 inhibitors and improve response assessment in a lung cancer murine model receiving immunotherapy
Presenter: Ander Puyalto
Session: Poster session 07
2242P - Engineering immune-cell targeting nanoparticles for precise delivery of loaded-cargo and enhanced immunotherapy efficacy
Presenter: Na Kyeong Lee
Session: Poster session 07
2243P - Immune-modulating magnetic nanoparticles to enhance the immune response for the treatment of breast cancer metastasis and recurrence
Presenter: Jaesung Lim
Session: Poster session 07
2244P - Anti CTLA-4 and PD-1 monoclonal antibodies increases systemic SDF-1 and galectin-3 levels through NLRP3 and MyD-88 pathways in preclinical models
Presenter: Vincenzo Quagliariello
Session: Poster session 07
2245P - Graphene oxide: A promising platform for delivery of cancer immunotherapy
Presenter: Sorayut Chattrakarn
Session: Poster session 07
2246P - Tumor-infiltrating lymphocites and gene expression across multiple cancer-types: A translational analysis from the SOLTI-1904-ACROPOLI study
Presenter: Elia Segui Solis
Session: Poster session 07